POMDOCTOR LIMITED

As of December 31, 2025, POMDOCTOR LIMITED carries a market capitalization of 1.23B, placing it among publicly traded companies globally. Its enterprise value stands at 1.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, POMDOCTOR LIMITED has 23.18M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, POMDOCTOR LIMITED maintains a current ratio of 0.48, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, POMDOCTOR LIMITED's stock has declined approximately 99.74% over the past 52 weeks. The 50-day moving average sits at 8.25, while the 200-day moving average is 30.28.

As of December 31, 2025, POMDOCTOR LIMITED holds 1.37M in cash and equivalents against 65.06M in total debt, resulting in a net debt position of 63.28M. Total book value stands at -64.92M, with working capital of -16.19M providing operational flexibility.

POMDOCTOR LIMITED's most recent stock split took place on October 21, 2026 with a 10:1 split ratio.